Sign Out
Special caution should be exercised in patients with: Hepatocellular insufficiency; severe renal insufficiency (creatinine clearance less than 30 mL/min); chronic alcoholism; nutritional dystrophy (reduced reserves of hepatic gluthatione); dehydration.
Risk of developing liver damage during the treatment with Infulgan increases in patients with alcoholic liver disease.
Administration of Infulgan may affect laboratory test results by altering the levels of serum glucose and serum uric acid.
Liver function monitoring and peripheral blood cell count are recommended in case of prolonged treatment.
Effect on the Ability to Drive and Operate Machinery: No effect.
Use in Children: Infulgan may be used in infants weighing more than 10 kg for symptomatic treatment of pain and hyperthermia in the post-surgical period only.
